Ophthalmologica recently published a research led by Professor Haritoglou from the Ludwig Maximillians University (LMU) Eye Hospital in Munich, Germany, that addresses a different potential application for the Microaneurysm (MA) analysis calculated by RetmarkerDR. Instead of using Retmarker to identify eyes at risk of developing CSME, this research looks at the effect of CSME treatment on MA activity.
Sixty nine eyes were followed, divided in two groups: the treated group with 3 Ranibizumab injections in a 4-week interval and a control group with non proliferative diabetic retinopathy only. For both groups retinal imaging was performed, before the treatment and 30 days after the last injection for the treated group, and 90 days apart for the control group. These images where then assessed using Retmaker automated analysis to calculate MA activity. Patients in the treated groups showed a significantly higher MA activity, whereas Patients in the untreated group MAs remained almost unchanged.
MA Analysis performed by RetmarkerDR is suggested to potentially be useful for assessing the response to Ranibizumab treatment.
More details about this publication can be found here.
Professor Cunha-Vaz has been selected to receive the Weisenfeld award in the ARVO 2014 Conference. This award recognizes distinguished scholarly contributions to the clinical practice of ophthalmology.
It is precisely Professor Cunha-Vaz's role as a “prolific innovator” that is underlined with this award. The award further recognizes four and a half decades of contributions to clinical and scientific literature, resulting in over 460 citations, as well as the leadership roles in academic placements and in clinical research institutions (eg. leading AIBILI, Retmarker’s clinical partner).
Being one of the most prestigious awards in our area, it is a tribute to Mildred Weisenfeld's outstanding contributions to the field, which include the founding of Fight for Sight in 1946. She believed that by encouraging research and researchers, the result would have a greater impact.
We at Critical Health enthusiastically congratulate Professor Cunha-Vaz for this well-deserved award and are grateful for the privilege of our collaborative work.
More details about this award can be found here.
Under this partnership the Department of Mathematics (DMUC) will collaborate with Critical Health to create an enhanced algorithm capable of automatically identifying lesions in retinal images from Diabetic patients.
The group lead by Professor Isabel Narra Figueiredo developed a new approach which makes use of advanced image processing techniques to be able to identify several lesions in retinal images. This new algorithm will be integrated in the Retmarker family of products to evaluate its impact in International Diabetic Retinopathy Screening programs.
More details can be found here (Portuguese version).
Critical Health participated in the recent HCIST 2013 (Conference on Health and Social Care Information Systems and Technologies). Our participation consisted on the presentation of two novel technical contributions, which are a result of Critical Health constant thrive for innovation.
One presentation dealt with the combination of image processing feature extraction methods, with efficient database query techniques, in order to achieve an efficient Image Recognition System. The results demonstrated how this combined approach enables a reduction of 86,20% in the processing time required for a total of almost 5000 images tested.
Another contribution was a case study report on the deployment of Medisoft Ophthalmology EMR on a Portuguese Ophthalmic Research Institution. This case study reports details on the translation of over 40.000 medical terms and expressions required, and on the identified key factors for a successful EMR deployment. If these are followed in order to achieve as early as possible User Involvement and Enthusiasm, then efficiency gains are expected and identified, namely in error reduction, increased quality of clinical data and prompt support for clinical studies.
More details about this publication can be found here.
A recent publication in RETINA, the journal of retinal and vitreous diseases (impact factor 2.825), depicts the results of a retrospective study that corroborates previous findings and publications on Retmarker being a biomarker for the progression of Diabetic Retinopathy. This important conclusion was presented by the group of researchers led by Professor Haritoglou from the Ludwig Maximillians University (LMU) Eye Hospital in Munich, Germany.
Patients were followed up for more than 5 years, and the conclusions show that the Microaneurysm Formation Rate as calculated by RetmarkerDR is predictive of the progression to Clinically Significant Macular Edema (CSME), a sight threatening complication of Diabetic Retinopathy.
The innovative automated analysis from RetmarkerDR may help to determine the individual risk of a patient, and thus schedule individual screening intervals.
More details about this publication can be found here.
Prof. Cunha-Vaz, AIBILI’s President and Retmarker’s Scientific Advisor, is the winner of the 2012 BIAL Award of Clinical Medicine for his work "Diabetic Retinopathy: new perspectives for personalized treatment."
The work highlights the importance of identifying patients in risk by means of biomarkers that allow predicting the progression of Diabetic Retinopathy in the early stages.
The Micronaneurysm Turnover, provided automatically by Retmarker software, is a biomarker for Diabetic Retinopathy worsening, a very useful tool for those caring for diabetics. The automated analysis from Retmarker only requires non-invasive colour fundus photography to provide such assessment.
Established in 1984, the Bial Award has been rewarding relevant health professionals from different countries, fostering the basic and the clinical research in the area of health. Taking place every two years, it is one of the most prestigious awards of scientific research in the area of health in Europe.
National Television interview with Professor Cunha-Vaz about the BIAL Award (Portuguese version only).
The March 2013 issue of Immunology, Endocrine and Metabolic Agents in Medical Chemistry (formerly 'Current Medicinal Chemistry - Immunology, Endocrine and Metabolic Agents') publishes an article entitled 'Surrogate Outcomes for Progression in the initial Stages of Diabetic Retinopathy'. The publication underlines the importance of evaluating treatment options for the earlier stages of the disease, since currently treatment options are only available for more advanced stages. Furthermore, the study stresses the existing need in clinical trials that test drug efficacy to have surrogate outcomes associated with clinically accepted outcomes.
The article from AIBILI reports on the value of using the automated analysis from RetmarkerDR to calculate Microaneurysm Turnover at the Macula, as a biomarker for diabetic retinopathy worsening. Furthermore, the conclusion also shows that besides the risk of worsening, the MA turnover automatically calculated can also be indicative for long term and short term predictions.
A biomarker for diabetic retinopathy worsening is a very useful instrument for those caring for diabetics. The automated analysis from Retmarker only requires non-invasive fundus photography to provide such assessment.
This journal from Dove Press (Volume 1 published in 2011) is one of the most thriving and dynamic publications in the field of biomarkers. It is a member of ResearGate network, DOAJ and OAIster, and a paradigm in the new wave of open access, peer reviewed scientific publications.
More details about the study can be found here.
CAO is the annual meeting of the Portuguese licensed Optometrists (APLO). Critical health was present at the eighth edition that took place in Coimbra, Portugal, on the 17th and 18th of November.
More than 200 Optometrists participated in the event and had the opportunity to learn about Retmarker technology. In particular it was possible to experiment and verify how Retmarker family of products can contribute to their practice. Retmarker automated analysis technology proves to be a valuable tool in helping to monitor pathologies that can lead to vision loss when untreated.
Details about the APLO and VIII CAO can be found here (Portuguese language only).
The German magazine Der AugenSpiegel published an article highlighting the importance of early detection of retinal changes in Diabetics, in order to prevent the onset of vision threatening conditions. The article also points out the difficulty of complying with yearly screening due to the increasing prevalence of Diabetes.
Dr. Christos Haritoglou from the Ludwig Maximillians University Hospital (LMU Munich) describes how RetmarkerDR has been validated on a retrospective study conducted by his team. The conclusion of the article is that the RetmarkerDR automated analysis tool proves to be valuable in a screening context, successfully identifying patients at higher risk of developing CSME.
More details about this publication can be found here (German language only).
The organization of the 12th EURETINA (Milan, 6-9 October 2012 invited Critical Health to participate in an Open Session on the topic "Diabetic Retinal Screening enters the 21st Century - New Technology for Old Problems".
Critical Health has shared the experience of the systems implemented in the central region of Portugal, where the Retmarker technology has already helped to screen over 20.000 patients. Additionally, some concepts of how to bring Retmarker technology to conveniently help more diabetics manage their condition have also been presented.
Details about Euretina'12 Open Session can be found here.
Universidade do Minho is organizing the 7th edition of the biggest Biomedical Engineering Meeting in Portugal. Critical Health has been invited to give a lecture on existing challenges for Biomedical Engineers in the work environment.
Critical Health has had both a close cooperation with several universities in R&D projects but also incorporates a motivated group of dedicated staff (the majority being biomedical engineers). It is a great pleasure to provide academics with feedback and to motivate graduate students to participate and propose new projects and ideas.
Através desta iniciativa a Associação Protectora dos Diabéticos de Portugal (APDP) procura dar continuidade ao trabalho desenvolvido junto das pessoas com diabetes onde já assistiu mais de 100 mil pessoas. A campanha tem também como função sensibilizar as pessoas para uma doença que já atinge um milhão de portugueses, sendo que 400 mil têm diabetes e não o sabem.
A campanha é nacional e todas as pessoas, com ou sem diabetes, são convidadas a aderir. Para ser sócio basta ligar o 213 816 107 ou efetuar a inscrição através do site www.apdp.pt
Critical Health was recognized by the Microsoft BizSpark initiative as Startup of the Day. Full details online at their website here.
Critical Health will be at the 11th EURETINA Congress (Booth 509, Level 5), taking place in London from 26th to 29th May, to showcase its latest innovations in retinal disease management to Ophthalmologists worldwide.
Recent results that will be presented at EURETINA corroborate previous
findings on the Microaneurysm Turnover biomarker.
See the english Press Release here.
Critical Health will be showcasing Retmarker decision support products and Medisoft's Ophthalmology Electronic Medical Record in the XVIII Pan-American Course of the Pan-American Association of Ophthalmology (Booth 035; 07th to 9th April; Estoril; Portugal).
Critical Health has complemented its portfolio with a specialized Ophthalmology Electronic Medical Record. The company set up a partnership with UK's leading provider, Medisoft, to commercialize their solution in Portugal, Spain and Latin America.
See the Portuguese Press Release here.
Retmarker was distinguished with an Honourable Mention in the COTEC‐UNICER Award for Innovation Products – an event supported by the Expresso Newspaper. The 7th COTEC National Innovation Encounter was dedicated to the theme “The Innovator’s DNA” and took place on May 31st in Estoril – Portugal.
Critical Health's is an approved Manufacturer of Medical Devices according to EC Directive 93/42/EEC Annex II, Article 3. The company's Quality Management System was certified by TÜV Rheinland according to EN ISO 13485:2003 + AC:2007 and EN ISO 9001:2008.
Retmarker was approved as Medical Device, entitled to display the CE 0197 mark.
Critical Health won an award at the European IT Excellence Awards in the category for Information Management, with one of its Retmarker product – Retmarker AMD. See the english Press Release here or the portuguese version here.
Critical Health Innovation in Retinal Disease Management at EURETINA'11
Critical Health incorporates Medisoft's Electronic Medical Record solution (PT)
Critical Health at Portugal Tecnológico 2010 (PT)
RetmarkerDR unveiled at the 10th EuRetina Congress in Paris
RetmarkerDR unveiled at the 10th EuRetina Congress in Paris (PT)
Retmarker receives honourable mention
Retmarker receives honourable mention (PT)
Critical Health and Retmarker certification
Critical Health and Retmarker certification (PT)
Critical Health wins European IT Excellence Award
Critical Health wins European IT Excellence Award (PT)
Critical Health at SPO (PT)
Carlton Life elects Critical Health's solution (PT)
Critical Health at AAO Joint Meeting (PT)
Critical Health at AAO Joint Meeting